**Lower bone turnover and relative bone deficits in men with metabolic syndrome: a matter of insulin sensitivity? The European Male Ageing Study**

Michaël R. Laurent, MD 1,2,3 \*, Michael J. Cook, MSc 4 \*, Evelien Gielen, MD PhD 1,3, Kate A. Ward, PhD 5, Leen Antonio, MD 2,6, Judith E. Adams, MBBS, FRCP, FRCR7, Brigitte Decallonne, MD PhD 6, György Bartfai, MD PhD 8, Felipe F. Casanueva, MD PhD 9, Gianni Forti, MD PhD 10, Aleksander Giwercman, MD PhD 11, Ilpo T. Huhtaniemi, MD PhD 12, Krzysztof Kula, MD PhD 13, Michael E. J. Lean, MA MD FRCP 14, David M. Lee, PhD 15, Neil Pendleton, MD 16, Margus Punab, MD PhD 17, Frank Claessens, PhD 2, Frederick C. W. Wu, MD FRCP 18, Dirk Vanderschueren, MD PhD 6, Stephen R. Pye, PhD 4 \*, Terence W. O’Neill, MD 4,19 \*; EMAS Group†

\* These authors contributed contributed equally to this manuscript.

1 Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, KU Leuven, Herestraat 49 PO box 7003, 3000 Leuven, Belgium

2 Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Herestraat 49 PO box 901, 3000 Leuven, Belgium

3 Center for Metabolic Bone Diseases, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium

4 Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, Manchester Academic Health Science Centre, University of Manchester, Stopford Building, Oxford Road, Manchester M13 9PT, UK

5 Elsie Widdowson Laboratory, Medical Research Council Human Nutrition Research, 120 Fulbourn Road, Cambridge, CB1 9NL, UK

6 Clinical and Experimental Endocrinology, Department of Clinical and Experimental Medicine, KU Leuven, Herestraat49 PO box 902, 3000 Leuven, Belgium

7 Radiology Department, and Manchester Academic Health Science Centre, Manchester Royal Infirmary, Central Manchester University Hospitals NHS Foundation Trust and University of Manchester, 46 Grafton Street, Manchester, M13 9NT UK

8 Department of Obstetrics, Gynecology and Andrology, Albert Szent-György Medical University, Semmelweis u. 1, H-6725 Szeged, Hungary

9 Department of Medicine, Santiago de Compostela University, Complejo Hospitalario Universitario de Santiago, CIBER de Fisiopatología Obesidad y Nutricion, Instituto Salud Carlos III, Travesía de Choupana s/n, 15706 Santiago de Compostela, Spain

10 Andrology Unit, Department of Clinical Physiopathology, University of Florence, Viale Pieraccini 6, 50139 Firenze, Italy

11 Department of Urology, Scanian Andrology Centre, Malmö University Hospital, University of Lund, Jan Waldenströms gata 35, 20502 Malmö, Sweden

12 Institute of Reproductive and Developmental Biology, Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London W12 0HS, UK

13 Department of Andrology and Reproductive Endocrinology, Medical University of Lodz, Pomorska 45/47, Śródmieście 90-406 Łódź, Poland

14 Department of Human Nutrition, School of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow G31 2ER, Scotland, UK

15 Cathie Marsh Institute for Social Research, School of Social Sciences, University of Manchester, Humanities Bridgeford Street-G17, Manchester M13 9PL, UK

16 School of Community Based Medicine, University of Manchester, Salford Royal NHS Trust, Stott Lane, Salford M6 8HD, UK

17 Andrology Unit, United Laboratories of Tartu University Clinics, L. Puusepa 1a, Tartu, Estonia

18 Developmental and Regenerative Biomedicine Research Group, Andrology Research Unit, Manchester Academic Health Science Centre, Manchester Royal Infirmary, University of Manchester, Grafton Street, Manchester M13 9WL, UK

19 NIHR Manchester Musculoskeletal Biomedical Research Unit, 29 Grafton Street, Manchester M13 9WU, UK

† The European Male Ageing Study (EMAS) Group: The Principal Investigator of EMAS is Prof. F. C. W. Wu. Participating centers: Florence (Gianni Forti, Luisa Petrone, Giovanni Corona); Leuven (Dirk Vanderschueren, Steven Boonen†, Herman Borghs); Łódź (Krzysztof Kula, Jolanta Slowikowska-Hilczer, Renata Walczak-Jedrzejowska); London (Ilpo Huhtaniemi); Malmö (Aleksander Giwercman); Manchester (Frederick C.W. Wu, Alan J. Silman, Terence W. O'Neill, Joseph D. Finn, Philip Steer, Abdelouahid Tajar, David M. Lee, Stephen R. Pye); Santiago de Compostela (Felipe Casanueva, Mary Lage, Ana I Castro); Szeged (György Bartfai, Imre Földesi, Imre Fejes); Tartu (Margus Punab, Paul Korrovitz); Turku (Min Jiang).

*Corresponding author:*

Michaël R. Laurent, M.D.

Phone: +32 (0)16 377500

Fax: +32 (0)16 345995

michael.laurent@med.kuleuven.be

**Funding:** The European Male Aging Study was funded by the Commission of the European Communities Fifth Framework Program, Quality of Life and Management of Living Resources, Grant QLK6-CT-2001-00258, by Arthritis Research UK, by the Research Foundation Flanders grants G.0171.03 and G.0854.13N and KU Leuven grant GOA/15/017. This report includes independent research supported by the U.K. National Institute for Health Research Biomedical Research Unit Funding Scheme. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. The work of K.A.W was conducted within the core programme of the MRC Nutrition and Bone Health Group at MRC Human Nutrition Research, funded by the UK Medical Research Council (Programme number U105960371). M.R.L. is a PhD Fellow of the Research Foundation Flanders. D.V. is a senior clinical investigator supported by the Clinical Research Fund of the University Hospitals Leuven, Belgium.

**Conflicts of interest:** All authors have completed the ICMJE uniform disclosure form at <http://www.icmje.org/coi_disclosure.pdf> and declare the following: Dr. Laurent has received lecture fees from Flanders’ Agricultural Marketing Board (VLAM) and reports consultancy for Novartis and Alexion. Dr. Huhtaniemi has consulted for and/or received research funding from Ferring, Novartis and Takeda. Dr. Wu has consulted for Besins Healthcare and Repros Inc., and received research funding from Besins Healthcare and Bayer Schering. All other authors declare that they have no conflict of interest.

**ABSTRACT** *(250 words)*

**Introduction:** Metabolic syndrome (MetS) has been associated with lower bone turnover and relative bone mass or strength deficits (i.e. not proportionate to body mass index, BMI), but the relative contributions of MetS components related to insulin sensitivity or obesity to male bone health remain unclear.

**Methods:** We determined cross-sectional associations of MetS, its components and insulin sensitivity (by homeostatic model assessment, HOMA-S) using linear regression models adjusted for age, center, smoking, alcohol and BMI. Bone turnover markers and heel broadband ultrasound attenuation (BUA) were measured in 3129 men aged 40-79. Two centers measured total hip, femoral neck and lumbar spine areal bone mineral density (aBMD, n=527) and performed radius peripheral quantitative computed tomography (pQCT, n=595).

**Results:** MetS was present in 975 men (31.2%). Men with MetS had lower β-CTX, PINP and osteocalcin (*P*<0.0001) and higher total hip, femoral neck and lumbar spine aBMD (*P≤*0.03). Among MetS components, only hypertriglyceridemia and hyperglycemia were independently associated with PINP and β-CTX. Hyperglycemia was negatively associated with BUA, hypertriglyceridemia with hip aBMD and radius CSA and stress-strain index. HOMA-S was similarly associated with PINP and β-CTX, BUA and radius CSA in BMI-adjusted models.

**Conclusions:** Men with MetS have higher aBMD in association with their greater body mass, while their lower bone turnover and relative deficits in heel BUA and radius CSA are mainly related to correlates of insulin sensitivity. Our findings support the hypothesis that underlying metabolic complications may be involved in bone’s failure to adapt to increasing bodily loads in men with MetS.

**Keywords:** Bone mineral density, bone turnover, male, metabolic syndrome, obesity, peripheral quantitative computed tomography

**Summary:** *(50 words)*

We examined cross-sectional associations of metabolic syndrome and its components with male bone turnover, density and structure. Greater bone mass in men with metabolic syndrome was related to their greater body mass, whereas hyperglycemia, hypertriglyceridemia or impaired insulin sensitivity were associated with lower bone turnover and relative bone mass deficits.

**Introduction**

The metabolic syndrome (MetS) encompasses several features –abdominal obesity, elevated blood pressure, dyslipidemia and hyperglycemia– which confer an increased risk of developing cardiovascular disease and type 2 diabetes mellitus (T2D) [1]. The usefulness of the MetS concept relies on the assumptions that (i) all components are important and treatable predictors of adverse cardiometabolic outcomes, (ii) MetS predicts these outcomes better than the sum of its individual components, and (iii) MetS predicts these outcomes better than simpler measures like body mass index (BMI). Indeed, instead of focusing on obesity, correlates (or consequences) of insulin resistance (hyperglycemia, hypertriglyceridemia) lie at the heart of the MetS concept [2]. Although MetS may be a useful construct to focus cardiovascular and T2D preventive strategies, the validity of this construct as well as its cut-off values remain debated. Nevertheless, all MetS components become increasingly prevalent with age, with around 25-35% of adults having MetS (depending on the definition and population studied) [3-7].

Osteoporosis is also a common age-related condition. With a male lifetime incidence of osteoporotic fractures as high as 20-25% in high-risk Caucasian populations, men contribute substantially to the overall fracture burden [8]. Contrary to the general belief that obesity is protective for the skeleton, a growing body of evidence suggests that the relationships between bone metabolism, obesity and insulin resistance are more complex. Both obesity and T2D have been associated with higher areal bone mineral density (aBMD) [9, 10], which however does not seem to confer protection against fractures [11-13]. This paradox may be explained by higher falls risk and impact force, altered material properties [14] as well as relative deficits in cortical bone structure and strength [10, 14-17]. This relative bone deficit involves greater absolute aBMD, cross-sectional bone area or volumetric BMD (vBMD) with increasing BMI [10], whereas associations of MetS or T2D with bone outcomes become negative in BMI-adjusted models [3-5, 7, 9] *i.e.* BMD or bone strength not being *as high* in MetS or T2D as would be expected based on BMI alone. In other words, bone strength adapts to increasing bodily loads, but this relationship becomes attenuated at higher levels of BMI. In a recent MrOS study for example, estimated hip bone strength increased linearly with BMI until it started to plateau around BMI 30 kg/m² [16]. Why the skeletal strength:load ratio flattens in obesity is incompletely understood, but metabolic complications may be involved since previous studies on MetS have consistently reported negative associations of MetS components with aBMD in BMI-adjusted models [7]. Given the high prevalence of obesity and MetS, a deeper understanding of their relation to bone turnover, aBMD and vBMD, bone structure and bone strength can offer potentially important insights into male bone health. Using data from the observational European Male Ageing Study (EMAS), we examined associations of MetS, its components as well as insulin sensitivity (HOMA-S) with bone turnover markers (BTMs), heel quantitative ultrasound (QUS), hip and spine aBMD and radius peripheral computed tomography (pQCT) measures.

**Methods**

***Participants***

The design, cohort profile and assessments of EMAS have been reported previously [18]. From 2003 to 2005, an age-stratified random population sample of men aged 40-79 was recruited by eight European centers: Manchester, United Kingdom; Leuven, Belgium; Malmö, Sweden; Tartu, Estonia; Łódź, Poland; Szeged, Hungary; Florence, Italy and Santiago de Compostela, Spain. Ethical approval was obtained according to local institutional requirements at all centers and all men provided written informed consent.

***Study questionnaires and clinical assessments***

Subjects completed a postal questionnaire which included questions about comorbidities, smoking and average number of days per week in which alcohol was consumed in the previous month. Standardized measurements were taken for height to the nearest mm using a stadiometer (Leicester Height Measure, SECA UK Ltd) and body weight to the nearest 0.1 kg using an electronic scale (SECA, model 8801321009), with monthly calibrations in each center. BMI was calculated as weight in kilograms divided by height (in meters) squared. Waist circumference was measured using anthropometric tape midway between the iliac crest and lowest ribs, and the median of three measurements was recorded. Seated blood pressure (Omron 500I, Omron Healthcare Ltd, Milton Keynes, UK) was measured after a 5 min rest period. Reuben’s Physical Performance Test (PPT) was assessed as time (in seconds) required for a 50-feet walk. Interviewer-assisted questionnaires included prescription and non-prescription medication, and the Physical Activity Scale for the Elderly (PASE).

***Biological measurements***

A fasting morning (before 10:00 a.m.) venous blood sample was obtained, from which serum was separated and stored at -80 °C until analysis. Methods of measurement for BTMs and hormones have been described in detail previously [19, 20]. Serum β C-terminal cross-linked telopeptide (β-CTX; β-Crosslaps, n=3018), N-terminal propeptide of type I procollagen (PINP, n=3020) and osteocalcin (stable N-MID fragment, n=1089 randomly selected subjects) were measured by electrochemiluminescence immunoassay (ECLIA) on the Elecsys 2010 automated analyser (Roche Diagnostics) [21]. The detection limits of these kits are 10 pg/ml, < 5 ng/ml and 0.5 ng/ml, and the intra-assay coefficient of variation (CV) < 5.0 %, <3.0 % and < 5.0 % for β-cTX, P1NP and osteocalcin, respectively. Glucose, cholesterol and triglyceride measurements were undertaken in each participating center. Insulin was assayed using quimioluminiscence at University of Santiago de Compostela. Indices of insulin resistance, sensitivity and bèta-cell mass were calculated using the homeostasis model assessment (HOMA-IR, HOMA-S, HOMA-B, respectively) [22]. The quantitative insulin sensitivity check index (QUICKI) was calculated as the inverse of the sum of the logarithms of fasting glucose and insulin concentrations [23]. Methods for other hormone measurements in EMAS have been reported previously [20, 24, 25].

***Definition of metabolic syndrome (MetS)***

MetS was defined according to the 2009 harmonized criteria [1]. Subjects were classified as having MetS (MetS+) when ≥ 3 of the following criteria were present: waist circumference > 102 cm, triglycerides ≥ 1.7 mmol/l (150 mg/dl), HDL cholesterol < 1.03 mmol/l (40 mg/dl), systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg or use of antihypertensive drugs, and fasting glucose ≥ 5.6 mmol/l (100 mg/dl) or use of antidiabetic drugs. In the analyses comparing MetS+ to MetS- subjects, those with missing data were excluded when MetS could not be classified with certainty [25].

***Quantitative ultrasound (QUS) of the heel***

In all centers, QUS of the left heel was performed with the Sahara Clinical Sonometer (Hologic, Inc., Waltham, MA, USA) using a standardized protocol [19]. Each center calibrated the device daily with the physical phantom provided by the manufacturer. All quality control results were sent to Leuven and found stable throughout the study. Outputs included broadband ultrasound attenuation (BUA), speed of sound (SOS), estimated BMD (eBMD = 0.002592 × (BUA+SOS) − 3.687) and quantitative ultrasound index (QUI, a measure of stiffness calculated as QUI = 0.41[SOS]  + 0.41[BUA] − 571). Short-term precision of the method was established by duplicate measurements performed in 20 randomly selected cohort members in Leuven. The *in vivo* CVs were 2.8, 0.3 and 2.3% for BUA, SOS and QUI, respectively. Ten repeat measurements were performed on a roving phantom at each center. Standardized CVs (root mean squared difference divided by range to mean ratio [26]) for within machine variability ranged by center: for SOS, from 1.0 to 5.6%, and BUA from 0.7 to 2.7%. Standardized CVs for between machine variability were 4.8% for BUA and 9.7% for SOS.

***Dual-energy X-ray absorptiometry (DXA) and radius pQCT***

Subjects in Leuven and Manchester had DXA and pQCT scans performed. For DXA, the same QDR 4500A Discovery scanners were used in both centers (Hologic Inc, Bedford, MA, USA). Lumbar spine (L1–4), femoral neck and total hip aBMD were measured as described previously [19]. All scans and analyses were performed by trained and certified DXA technicians. The Hologic spine phantom was scanned daily to monitor the device performance and long-term stability. The precision errors (CV%) were 0.57% and 0.97% at L1-4, 1.28% and 2.04% at the femoral neck, and 0.56% and 0.97% at the total proximal femur in Leuven (n=20) and Manchester (n=31), respectively. Devices in Leuven and Manchester were cross-calibrated with the European spine phantom.

The pQCT protocol has been described previously [24]. In both centers, the non-dominant radius was measured using an XCT-2000 scanner (Stratec, Pforzheim, Germany) following the manufacturer's standard quality assurance procedures. Total and trabecular vBMD (mg/mm3), trabecular area and total cross-sectional area (CSA) (mm2) were measured at the distal (4%) radius (voxel size 0.4 mm). Cortical vBMD (mg/mm3), total CSA, cortical and medullary area (mm2), cortical thickness (mm), stress strain index (SSI) (mm3) and muscle CSA (mm2) were measured at the midshaft (50%) radius (voxel size 0.6 mm). The European Forearm Phantom (EFP) was measured in both centers; 10 repeat measurements were taken in slices 1–4. Differences were less than precision error for total, trabecular and cortical vBMD, and cortical area; therefore, cross-calibration was omitted. The short term precision of 2 repeat measurements with repositioning were: total vBMD 2.1% and 1.3%; trabecular vBMD 1.27% and 1.42%; cortical vBMD 0.77% and 0.71%; and cortical area 2.4% and 1.3% in Manchester (n = 22) and Leuven (n = 40), respectively.

***Statistical analyses***

Cross-sectional differences between MetS+ and MetS- groups were assessed by Mann-Whitney U-test and chi-square for continuous and categorical variables, respectively. Linear regression analysis of the association between metabolic (independent) and bone (outcome) variables were performed (i) unadjusted, (ii) adjusted for potential confounders (age, center, smoking and alcohol intake), (iii) adjusted for these confounders plus other MetS components (to examine whether individual MetS component demonstrate associations independent of other MetS components), or (iv) adjusted for confounders plus BMI. Associations are reported as standardized (z-score) β regression coefficients. Analyses were performed using Stata version 13.1 (StataCorp, College Station, TX, USA), and two-tailed *P* < 0.05 was considered significant. No adjustments for multiple testing were applied.

**Results**

***Study population and characteristics***

Of 3369 men in the baseline cohort, we excluded men taking glucocorticoids, drugs with possible hormonal effects (incl. sex steroids, gonadorelin analogues, strong opioids, and drugs for thyroid disorders), bone-active treatments (incl. bisphosphonates, calcium and/or vitamin D supplements), HIV drugs or men in whom MetS status could not be determined due to missing values. The total number of exclusion was 240 (7.12%), leaving 3129 men in the analytical sample. Of these, 975 (31.2%) were classified as having MetS, *i.e.* satisfying at least three MetS criteria. There were 257 (8.2%), 961 (30.7%), 936 (29.9%), 627 (20.0%), 284 (9.1%) and 64 (2.0%) men satisfying exactly 0, 1, 2, 3, 4 or 5 MetS criteria, respectively. Apart from having more MetS features, men with MetS were older, heavier, more often former smokers and less frequent drinkers (*Table 1*). They also had an altered endocrine profile, walked slower and reported less physical activity (*Supplemental Table 1*).

***Associations between MetS, its components and bone turnover markers***

Men with MetS had significantly lower levels of PINP, osteocalcin and particularly β-CTX (*Table 1*). In linear regression analyses, MetS (*Table 2*) was associated with lower BTMs, independent of confounders (age, center, smoking and alcohol; Model 1) and BMI (Model 3), except for osteocalcin. However, when MetS components were analyzed individually, only hypertriglyceridemia and hyperglycemia were inversely associated with PINP and β-CTX, independent from other MetS components (Model 2) or BMI (Model 3). Osteocalcin was independently and inversely associated only with hyperglycemia (Model 3). Also when analyzed as continuous variables, glucose and triglycerides showed independent inverse associations with β-CTX, PINP and osteocalcin, whereas blood pressure, HDL and waist circumference did not (*data not shown*). Insulin sensitivity (HOMA-S or QUICKI) was also associated with PINP and β-CTX, independently of age, center, smoking, alcohol and BMI (*Supplemental Table 2*). Adjustment for differences in either physical activity/performance, sex steroids, PTH, 25-OH-vitamin D, IGF-1 or CRP (*Supplemental Table 1*) did not alter the associations between MetS and BTMs (*data not shown*). Compared to the referent group of men satisfying exactly two MetS criteria, men with three, four or five MetS criteria had lower BTMs (*Suppl. Fig. 1A-B*). However, men with one or zero criteria also had higher BTMs, implying that there is no clear threshold at three MetS criteria above which BTMs are altered.

***Associations between MetS, its components and heel QUS parameters***

Following adjustment for age, center, smoking and alcohol, MetS was positively associated with BUA and QUI (*Table 3*) but not SOS or eBMD (*data not shown*). When adjusted for BMI however, these associations became non-significant. When individual MetS components were examined (*Table 3*), only waist >102 cm was positively associated with BUA and QUI (as well as SOS and eBMD, *not shown*), although not independently from BMI. In fact, BMI adjustment (Model 3) revealed a negative association of hyperglycemia with BUA. Also when analyzed as continuous variables, glucose and triglycerides where inversely associated with BUA and QUI the BMI-adjusted model (*data not shown*). Fasting insulin levels and markers of insulin resistance were also negatively associated with BUA, SOS, QUI and eBMD, but again this was only evident following BMI adjustment (*Supplemental Table 2*). BMI itself was positively associated with QUS parameters (*Supplemental Table 2*). Adjustment for differences in either physical activity/performance, sex steroids, PTH, 25-OH-vitamin D, IGF-1 or CRP (*Supplemental Table 1*) did not affect the associations between MetS and QUS parameters (*data not shown*). Men with four MetS criteria had significantly higher BUA and QUI compared to the referent group of men satisfying two MetS criteria in unadjusted and confounder-adjusted analyses, but this was not the case for men meeting all five MetS criteria (*Suppl. Fig. 1C-D*). In fact, adjustment for BMI revealed significantly lower BUA and QUI in men with full MetS.

***Associations of MetS and its components with aBMD and pQCT outcomes***

A subgroup of men from Manchester and Leuven underwent DXA (n=527) and radius pQCT (n=595). Men with MetS had higher aBMD at the lumbar spine, total hip and femoral neck (*Table 1*). MetS was positively associated with aBMD at all three sites independent of confounders, but not following BMI adjustment (*Table 4*). Among MetS components, waist > 102 cm and hyperglycemia were independently associated with aBMD at all three sites, but not independent from BMI (*Table 4*). Interestingly, hypertriglyceridemia was inversely associated with femoral neck aBMD when adjusted for other MetS components or BMI.

Men with MetS had higher muscle area, with a trend towards greater cortical bone area (*P*=0.053) and lower muscle density (*P*=0.06) (*Table 1*). In linear regression analyses, MetS as a whole was not associated with skeletal pQCT parameters (*data not shown*). Among MetS components, waist circumference was independently associated with greater CSA at the ultradistal (*not shown*) and midcortical site, cortical thickness and bone area, SSI and muscle area (*Table 4*). Hypertriglyceridemia (or triglycerides as a continous variable, *data not shown*) was negatively associated with CSA and SSI independent from other MetS components or BMI, and with cortical bone area when adjusted for BMI (*Table 4*). Both at the ultradistal and mid-radius, MetS or its components were not associated with vBMD (*data not shown*). Cortical bone area, CSA and SSI were also associated with HOMA-S and QUICKI, but only in BMI-adjusted models (*Supplemental Table 2*).

**Discussion**

MetS is fairly common in the general population; in line with previous studies [3-7, 9], almost one-third of our 40-79 year-old European men qualified under recent international criteria [1]. Our main findings are that in men with MetS, the lower bone turnover and greater bone mass at loaded sites (as reflected by heel BUA and total hip, femoral neck and lumbar spine aBMD) are not uniformly associated with all MetS components. The lower bone turnover was mainly associated with MetS components related to insulin sensitivity (hyperglycemia, hypertriglyceridemia) or indices thereof (HOMA-S, QUICKI). On the other hand, the association of MetS with greater bone mass was determined by greater body mass (either by waist circumference or BMI) and not present at the radius, despite greater forearm muscle area. The associations of MetS with lower BTMs and superior QUS parameters in the overall cohort did not appear to be explained by higher free/bioavailable E2 levels (*data not shown*) and occurred in spite of an otherwise adverse endocrine/biochemical profile in men with MetS (*Supplementary Table 1*).

There is agreement in the literature that MetS is not an overall valid construct in relation to bone health because not all components of MetS have similar associations with skeletal outcomes [3, 5, 9]. Previous studies in older men have shown that MetS or hyperglycemia are inversely associated with BTMs as the outcome [5, 6, 27]. However, these studies have not reported association of individual MetS components with BTMs independent from other MetS components. Our finding that not only hyperglycemia but also hypertriglyceridemia was independently associated with BTMs is of interest given that triglycerides were strongly related to aBMD and fracture risk in two previous studies [3, 5]. We reasoned that insulin sensitivity could explain the association with hyperglycemia and hypertriglyceridemia, and indeed found that indices like HOMA-S and QUICKI were independently associated with bone turnover (*Supplementary Table 2*). The finding that men with greater waist circumference or BMI have higher absolute heel QUS parameters, hip and spine aBMD and mid-radius cortical bone and muscle area are also in accordance with previous studies [3, 9, 10, 12, 13, 16] and consistent with the hypothesis that bone mass in obesity is adapted to greater bodily loads.

Importantly however, adjusting for BMI revealed *inverse* associations of hyperglycemia with heel BUA, and of hypertriglyceridemia with aBMD at the total hip, femoral neck as well as radius cortical bone area, CSA and SSI. This is in agreement with previous observations in T2D [11, 15] and several studies on MetS and male bone health [3-5, 9] which also found aBMD, bone width or strength to be increased in absolute terms, but not in BMI-adjusted models i.e. not *as much* as could have been expected for body weight. Similarly, we found that men with MetS had greater forearm muscle area (*Table 1*) which was entirely related to their higher waist circumference or BMI (*Table 4*). However, this should not be taken to imply superior muscle mass (let alone strength) in obese people, given the limitations of pQCT in assessing adipose infiltration which occurs interstitially, inter- and intracellularly in muscle (as suggested by the trend towards lower muscle density; *Table 1*).

What exactly drives the non-linear relationship or plateau in the bone strength-BMI relationship remains unknown [16, 28]. Among the possibilities we examined, the relative skeletal deficits in men with MetS did not appear to be associated with adverse biochemical/endocrine factors or decreased physical activity/ performance. Instead, our data suggest that the greater bone mass was strongly determined by obesity, but obese subjects are also prone to higher fasting glucose and triglyceride levels and reduced insulin sensitivity (*Supplementary Table 2*) which may in turn play a negative role and mitigate the stimulatory effect of body mass. Further research is however needed to investigate whether detrimental skeletal effects derive directly from high glucose or triglyceride levels, indirectly from impaired insulin signaling, or both.

The negative association of hypertriglyceridemia with cortical bone area and strength (as reflected by the SSI) was explained by decreased bone width (as reflected by CSA, a measure of periosteal bone expansion). Even when cortical thickness or vBMD were unaffected in our population-based study, bone size is known to be a major determinant of bone strength. A recent study also reported that bone width at the femoral neck (estimated by DXA) was lower in MetS, although the results in men were only borderline significant [9]. In contrast, Szulc *et al*. suggested that MetS affects mainly BMC rather than bone size [5]. However, these previous DXA-based findings are more likely to be confounded by projectional artifacts than our pQCT results.

Our study has several strengths including its large, geographically diverse random sample of European men. The age range was broad, but the associations of MetS and its components with BTMs and QUS were similar across 10-year age bands or in subgroups aged < 60 vs. ≥ 60 years (*data not shown*). This is the first study of bone health in MetS with pQCT data. Limitations include lack of prospective analyses or fracture outcomes and, like any observational study, we cannot confirm causality (nor exclude reverse causation). Although mounting evidence supports the assumptions that obesity and insulin signaling affect the skeleton [17, 29, 30], our findings remain hypothesis-generating. Furthermore, measurements of glucose and lipids were not centralized, although these measurements are generally well standardized. There is considerable interest in the role of undercarboxylated osteocalcin [29], but only total osteocalcin was available for a randomly selected subsample of men in our study. The lack of association of MetS or hypertriglyceridemia with osteocalcin (*Table 2*) likely resulted from lack of statistical power compared to PINP or β-CTX. In recent studies however, T2D or MetS in older men were not only associated with lower undercarboxylated osteocalcin but also lower total osteocalcin [27], PINP as well as β-CTX [31, 32], indicating that lower bone turnover in human insulin resistant states is not uniquely associated with undercarboxylated osteocalcin. The associations reported with dichotomized MetS components were confirmed in sensitivity analyses with continuous variables (*data not shown*). Thus, the lack of associations of skeletal outcomes with e.g. hypertension was not explained by the fact that according to the MetS cut-off, almost 80% of MetS– men still had a blood pressure ≥ 130/85 mmHg (Supplementary Table 1). Finally, obesity or T2D may be associated with spinal osteoarthritis [28] or increased cortical porosity [14, 15], but vertebral X-rays or high-resolution pQCT were unavailable in this study.

In summary, MetS is associated with lower bone turnover and higher bone mass at the heel, hip and spine. In line with previous studies however, MetS does not seem to be a useful unifying construct in relation to bone health, because (i) not all components were individual predictors of skeletal outcomes and (ii) there was no clear cut-off for number of MetS criteria above which BTMs or bone mass were dose-dependently affected (*Suppl. Fig. 1*). Instead, we found differential associations of lower bone turnover mainly with correlates of insulin resistance, and of body mass (either by waist circumference or BMI) with higher heel BUA, hip and spine aBMD and radius CSA. Importantly, BMI adjustment revealed negative associations between markers of insulin resistance and bone mass, suggesting that the positive effects of bodily loads on bone may be partially offset by concomitant metabolic derangements. In terms of clinical implications, these findings offer a note of caution against false reassurance by low BTMs or absence of low BMD in men with obesity, MetS and/or insulin resistance.

**References**

1. Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640-1645

2. Reaven GM (2011) Insulin resistance: the link between obesity and cardiovascular disease. Med Clin North Am 95:875-892

3. von Muhlen D, Safii S, Jassal SK, Svartberg J, Barrett-Connor E (2007) Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study. Osteoporos Int 18:1337-1344

4. Kinjo M, Setoguchi S, Solomon DH (2007) Bone mineral density in adults with the metabolic syndrome: analysis in a population-based U.S. sample. J Clin Endocrinol Metab 92:4161-4164

5. Szulc P, Varennes A, Delmas PD, Goudable J, Chapurlat R (2010) Men with metabolic syndrome have lower bone mineral density but lower fracture risk--the MINOS study. J Bone Miner Res 25:1446-1454

6. Hernandez JL, Olmos JM, Pariente E, Martinez J, Valero C, Garcia-Velasco P, Nan D, Llorca J, Gonzalez-Macias J (2010) Metabolic syndrome and bone metabolism: the Camargo Cohort study. Menopause 17:955-961

7. Esposito K, Chiodini P, Capuano A, Colao A, Giugliano D (2013) Fracture risk and bone mineral density in metabolic syndrome: a meta-analysis. J Clin Endocrinol Metab 98:3306-3314

8. Vanderschueren D, Laurent MR, Claessens F, Gielen E, Lagerquist MK, Vandenput L, Borjesson AE, Ohlsson C (2014) Sex steroid actions in male bone. Endocr Rev 35:906-960

9. Muka T, Trajanoska K, Kiefte-de Jong JC et al (2015) The Association between Metabolic Syndrome, Bone Mineral Density, Hip Bone Geometry and Fracture Risk: The Rotterdam Study. PLoS One 10:e0129116

10. Evans AL, Paggiosi MA, Eastell R, Walsh JS (2015) Bone Density, Microstructure and Strength in Obese and Normal Weight Men and Women in Younger and Older Adulthood. J Bone Miner Res 30:920-928

11. Schwartz AV, Vittinghoff E, Bauer DC et al (2011) Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 305:2184-2192

12. Johansson H, Kanis JA, Oden A et al (2014) A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res 29:223-233

13. Chan MY, Frost SA, Center JR, Eisman JA, Nguyen TV (2014) Relationship between body mass index and fracture risk is mediated by bone mineral density. J Bone Miner Res 29:2327-2335

14. Farr JN, Drake MT, Amin S, Melton LJ, 3rd, McCready LK, Khosla S (2014) In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res 29:787-795

15. Yu EW, Putman MS, Derrico N, Abrishamanian-Garcia G, Finkelstein JS, Bouxsein ML (2015) Defects in cortical microarchitecture among African-American women with type 2 diabetes. Osteoporos Int 26:673-679

16. Shen J, Nielson CM, Marshall LM, Lee DC, Keaveny TM, Orwoll ES (2015) The Association Between BMI and QCT-Derived Proximal Hip Structure and Strength in Older Men: A Cross-Sectional Study. J Bone Miner Res 30:1301-1308

17. Ishii S, Cauley JA, Greendale GA, Nielsen C, Karvonen-Gutierrez C, Ruppert K, Karlamangla AS (2014) Pleiotropic effects of obesity on fracture risk: the Study of Women's Health Across the Nation. J Bone Miner Res 29:2561-2570

18. Lee DM, Pye SR, Tajar A et al (2013) Cohort profile: the European Male Ageing Study. Int J Epidemiol 42:391-401

19. Boonen S, Pye SR, O'Neill TW et al (2011) Influence of bone remodelling rate on quantitative ultrasound parameters at the calcaneus and DXA BMDa of the hip and spine in middle-aged and elderly European men: the European Male Ageing Study (EMAS). Eur J Endocrinol 165:977-986

20. Vanderschueren D, Pye SR, O'Neill TW et al (2013) Active vitamin D (1,25-dihydroxyvitamin D) and bone health in middle-aged and elderly men: the European Male Aging Study (EMAS). J Clin Endocrinol Metab 98:995-1005

21. Rosenquist C, Qvist P, Bjarnason N, Christiansen C (1995) Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 41:1439-1445

22. Levy JC, Matthews DR, Hermans MP (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191-2192

23. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402-2410

24. Ward KA, Pye SR, Adams JE et al (2011) Influence of age and sex steroids on bone density and geometry in middle-aged and elderly European men. Osteoporos Int 22:1513-1523

25. Antonio L, Wu FC, O'Neill TW et al (2015) Associations between Sex Steroids and the Development of Metabolic Syndrome: a Longitudinal Study in European Men. J Clin Endocrinol Metab 100:1396-1404

26. Miller CG, Herd RJ, Ramalingam T, Fogelman I, Blake GM (1993) Ultrasonic velocity measurements through the calcaneus: which velocity should be measured? Osteoporos Int 3:31-35

27. Yeap BB, Chubb SA, Flicker L, McCaul KA, Ebeling PR, Beilby JP, Norman PE (2010) Reduced serum total osteocalcin is associated with metabolic syndrome in older men via waist circumference, hyperglycemia, and triglyceride levels. Eur J Endocrinol 163:265-272

28. Yusuf E (2012) Metabolic factors in osteoarthritis: obese people do not walk on their hands. Arthritis Res Ther 14:123

29. Clemens TL, Karsenty G (2011) The osteoblast: an insulin target cell controlling glucose homeostasis. J Bone Miner Res 26:677-680

30. Parajuli A, Liu C, Li W et al Bone's responses to mechanical loading are impaired in type 1 diabetes. Bone 81:152-160

31. Yeap BB, Alfonso H, Paul Chubb SA et al (2014) Higher serum undercarboxylated osteocalcin and other bone turnover markers are associated with reduced diabetes risk and lower estradiol concentrations in older men. J Clin Endocrinol Metab 100:63-71

32. Confavreux CB, Szulc P, Casey R, Varennes A, Goudable J, Chapurlat RD (2014) Lower serum osteocalcin is associated with more severe metabolic syndrome in elderly men from the MINOS cohort. Eur J Endocrinol 171:275-283

**Tables**

**Table 1:** Characteristics of men without and with metabolic syndrome.

|  |  |  |  |
| --- | --- | --- | --- |
|  | MetS –*n*=2154 | MetS +*n* = 975 | *P* value |
| Age (years) | 58.3 (49.4, 68.8) | 60.7 (52.0, 70.4)\* | 0.0001 |
| Weight (kg) | 78.6 (71.8, 86.0) | 91.7 (82.9, 101.1)\* | < 0.0001 |
| Height (cm) | 173.4 (168.6, 178.5) | 173.9 (168.8, 179.0) | 0.20 |
| BMI (kg/m2) | 26.2 (24.1, 28.2) | 30.4 (28.1, 32.8)\* | < 0.0001 |
| Current smoker | 474 [22.2%] | 193 [20.0%] | 0.16 |
| Ever smoker | 1446 [68.4%] | 718 [74.6%]\* | 0.001 |
| Alcohol every day | 356 [16.6 %] | 132 [13.6 %] | 0.06 |
| 5-6 days/week | 163 [7.6 %] | 54 [5.6 %] |
| 3-4 days/week | 265 [12.4 %] | 128 [13.2 %] |
| 1-2 days/week | 444 [20.8 %] | 204 [21.1 %] |
| < once/week | 578 [27.0 %] | 285 [29.4 %] |
| none | 334 [15.6 %] | 166 [17.1 %] |
| Waist circumference (cm) | 94.5 (88.4, 99.8) | 106.5 (102.2, 113.0)\* | < 0.0001 |
| Systolic BP (mmHg) | 142.0 (128.5, 155.0) | 150.0 (139.0, 164.0)\* | < 0.0001 |
| Diastolic BP (mmHg) | 85.0 (78.0, 93.0) | 90.0 (82.0, 98.0)\* | < 0.0001 |
| HDL cholesterol (mmol/l) | 1.4 (1.2, 1.7) | 1.2 (1.0, 1.4)\* | 0.0001 |
| Triglycerides (mmol/l) | 1.1 (0.8, 1.5) | 2.0 (1.4, 2.7)\* | < 0.0001 |
| Fasting glucose (mmol/l) | 5.2 (4.8, 5.5) | 5.9 (5.5, 6.7)\* | < 0.0001 |
| Bone turnover markers |  |  |  |
| PINP (µg/l) | 40.0 (31.0, 51.0) | 35.2 (27.4, 47.2)\* | < 0.0001 |
| Osteocalcin (µg/l) | 21.6 (18.0, 26.4) | 19.1 (15.3, 24.6)\* | < 0.0001 |
| β-CTX (ng/l) | 339.8 (245.3, 470.4) | 279.1 (183.3, 406.1)\* | < 0.0001 |
| QUS parameters | ***n*=2106** | ***n*=936** |  |
| BUA (dB/MHz) | 78.9 (67.5, 92.1) | 80.0 (69.1, 92.6) | 0.10 |
| SOS (m/s) | 1548.1 (1527.9, 1571.2) | 1547.5 (1527.7, 1567.8) | 0.73 |
| eBMD (g/cm2) | 0.531 (0.452, 0.618) | 0.536 (0.454, 0.618) | 0.64 |
| QUI | 96.1 (83.6, 109.9) | 96.8 (83.9, 109.9) | 0.60 |
| DXA: aBMD (g/cm2) | ***n*=401** | ***n*=126** |  |
| Lumbar spine (L 1-4) | 1.029 (0.927, 1.126) | 1.076 (0.970, 1.234)\* | 0.0004 |
| Total hip | 1.002 (0.925, 1.105) | 1.049 (0.950, 1.160)\* | 0.006 |
| Femoral neck | 0.796 (0.724, 0.890) | 0.821 (0.734, 0.927)\* | 0.03 |
| pQCT: 50% radius | ***n*=458** | ***n*=137** |  |
| Cortical bone area (mm2) | 105.3 (97.0, 115.0) | 108.8 (99.8, 117.0) | 0.05 |
| Cortical thickness (mm) | 3.2 (3.0, 3.5) | 3.3 (3.1, 3.6) | 0.17 |
| Cross-sectional area (mm2) | 147.2 (133.6, 161.8) | 149.0 (137.5, 164.2) | 0.34 |
| Stress strain index (mm3) | 328.9 (288.9, 381.5) | 344.9 (295.4, 390.8) | 0.10 |
| Medullary area (mm2) | 39.9 (32.3, 49.8) | 40.0 (32.5, 46.3) | 0.70 |
| Muscle area (mm2) | 3612.5 (3184.2, 4045.0) | 3782.0 (3448.8, 4229.8)\* | 0.0002 |
| Muscle density (mg/cm3) | 82.9 (81.2, 84.2) | 82.4 (80.4, 84.1) | 0.06 |
|  4% radius |  |  |  |
| Trabecular density (mg/cm3) | 205.7 (178.1, 233.3) | 205.8 (170.7, 234.7) | 0.65 |

Values are expressed as median (IQR) or *n* [%]

**Table 2:** Associations of MetS and its components with bone turnover markers.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Univariate | Model 1† | Model 2‡ | Model 3 § |
| **β-CTX** MetS | -0.35 (-0.42, -0.27)\* | -0.34 (-0.42, -0.26)\* | - | -0.26 (-0.35, -0.17)\* |
| Waist >102 cm | -0.24 (-0.31, -0.16)\* | -0.24 (-0.32, -0.17)\* | -0.16 (-0.24, -0.08)\* | -0.09 (-0.19, 0.02) |
| Triglycerides >150 mg/dL | -0.24 (-0.32, -0.17)\* | -0.23 (-0.31, -0.16)\* | -0.16 (-0.24, -0.08)\* | -0.17 (-0.25, -0.09)\* |
| HDL <40 mg/dL | -0.12 (-0.22, -0.01)\* | -0.14 (-0.24, -0.03)\* | -0.03 (-0.14, 0.08) | -0.07 (-0.18, 0.04) |
| Hypertension | -0.13 (-0.23, -0.03)\* | -0.10 (-0.20, 0.00) | -0.02 (-0.12, 0.09) | -0.02 (-0.12, 0.08) |
| Hyperglycemia | -0.30 (-0.37, -0.22)\* | -0.30 (-0.37, -0.22)\* | -0.25 (-0.32, -0.17)\* | -0.25 (-0.33, -0.17)\* |
| **PINP** MetS | -0.19 (-0.26, -0.11)\* | -0.18 (-0.26, -0.11)\* | - | -0.20 (-0.29, -0.11)\* |
| Waist >102 cm | -0.10 (-0.17, -0.02)\* | -0.10 (-0.17, -0.02)\* | -0.04 (-0.12, 0.04) | -0.07 (-0.18, 0.03) |
| Triglycerides >150 mg/dL | -0.16 (-0.24, -0.08)\* | -0.16 (-0.24, -0.08)\* | -0.13 (-0.21, -0.05)\* | -0.16 (-0.24, -0.08)\* |
| HDL <40 mg/dL | -0.03 (-0.14, 0.08) | -0.05 (-0.16, 0.06) | 0.00 (-0.12, 0.11) | -0.03 (-0.14, 0.08) |
| Hypertension | -0.07 (-0.17, 0.02) | -0.04 (-0.14, 0.06) | 0.02 (-0.09, 0.12) | -0.02 (-0.12, 0.09) |
| Hyperglycemia | -0.21 (-0.29, -0.14)\* | -0.21 (-0.28, -0.13)\* | -0.19 (-0.27, -0.11)\* | -0.21 (-0.29, -0.14)\* |
| **Osteocalcin** MetS | -0.26 (-0.39, -0.12)\* | -0.29 (-0.43, -0.15)\* | - | -0.15 (-0.31, 0.00) |
| Waist >102 cm | -0.25 (-0.38, -0.12)\* | -0.27 (-0.40, -0.14)\* | -0.21 (-0.35, -0.08)\* | -0.08 (-0.26, 0.10) |
| Triglycerides >150 mg/dL | -0.20 (-0.34, -0.07)\* | -0.23 (-0.37, -0.09)\* | -0.16 (-0.31, -0.02)\* | -0.13 (-0.27, 0.02) |
| HDL <40 mg/dL | 0.01 (-0.15, 0.17) | -0.06 (-0.23, 0.11) | 0.07 (-0.11, 0.24) | 0.02 (-0.15, 0.19) |
| Hypertension | -0.19 (-0.34, -0.04)\* | -0.13 (-0.29, 0.03) | -0.04 (-0.20, 0.12) | -0.03 (-0.20, 0.13) |
| Hyperglycemia | -0.25 (-0.38, -0.12)\* | -0.26 (-0.39, -0.12)\* | -0.20 (-0.34, -0.07)\* | -0.19 (-0.33, -0.06)\* |

\**P*<0.05. Results are expressed as z-score β-coefficients (95% CI). † Model 1:Adjusted for age, centre, smoking, alcohol ‡ Model 2: Adjusted for age, centre, smoking, alcohol and other MetS components § Model 3: Adjusted for age, center, smoking, alcohol and BMI

**Table 3:** Associations of MetS and its components (dichotomized) with QUS parameters.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Univariate | Model 1† | Model 2‡ | Model 3§ |
| **BUA** MetS | 0.10 (0.02, 0.17)\* | 0.11 (0.03, 0.19)\* | - | -0.05 (-0.14, 0.03) |
| Waist >102 cm | 0.18 (0.11, 0.25)\* | 0.20 (0.13, 0.28)\* | 0.22 (0.14, 0.30)\* | 0.00 (-0.11, 0.10) |
| Triglycerides >150 mg/dL | 0.01 (-0.07, 0.09) | 0.01 (-0.07, 0.08) | -0.02 (-0.10, 0.06) | -0.07 (-0.15, 0.01) |
| HDL <40 mg/dL | 0.04 (-0.06, 0.15) | 0.05 (-0.06, 0.15) | 0.01 (-0.10, 0.12) | -0.01 (-0.12, 0.10) |
| Hypertension | -0.02 (-0.12, 0.08) | 0.02 (-0.08, 0.12) | 0.00 (-0.10, 0.10) | -0.06 (-0.16, 0.04) |
| Hyperglycemia | -0.03 (-0.10, 0.05) | -0.01 (-0.08, 0.07) | -0.04 (-0.12, 0.04) | -0.09 (-0.16, -0.01)\* |
| **QUI** MetS | 0.06 (-0.01, 0.14) | 0.08 (0.01, 0.16)\* | - | -0.05 (-0.13, 0.04) |
| Waist >102 cm | 0.12 (0.04, 0.19)\* | 0.14 (0.07, 0.22)\* | 0.16 (0.08, 0.24)\* | -0.02 (-0.13, 0.08) |
| Triglycerides >150 mg/dL | 0.00 (-0.08, 0.08) | 0.00 (-0.08, 0.07) | -0.02 (-0.10, 0.06) | -0.07 (-0.15, 0.01) |
| HDL <40 mg/dL | 0.03 (-0.08, 0.13) | 0.03 (-0.08, 0.14) | 0.00 (-0.11, 0.11) | -0.01 (-0.12, 0.09) |
| Hypertension | -0.06 (-0.16, 0.04) | 0.00 (-0.10, 0.10) | -0.01 (-0.11, 0.09) | -0.07 (-0.17, 0.04) |
| Hyperglycemia | -0.04 (-0.11, 0.03) | -0.01 (-0.08, 0.06) | -0.03 (-0.11, 0.05) | -0.07 (-0.15, 0.00) |

\**P*<0.05. Results are expressed as z-score β-coefficients (95% CI). † Model 1:Adjusted for age, centre, smoking, alcohol ‡ Model 2: Adjusted for age, centre, smoking, alcohol and other MetS components § Model 3: Adjusted for age, center, smoking, alcohol and BMI

**Table 4:** Associations of MetS and its components (dichotomized) with aBMD and pQCT parameters.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|   | Univariate | Model 1† | Model 2‡ | Model 3§ |
|  **aBMD (g/cm2) L1-4:** MetS | 0.41 (0.21, 0.61)\* | 0.36 (0.16, 0.57)\* | - | 0.07 (-0.15, 0.29) |
| Waist >102 cm | 0.48 (0.29, 0.67)\* | 0.45 (0.26, 0.64)\* | 0.42 (0.22, 0.62)\* | 0.07 (-0.19, 0.33) |
| Triglycerides >150 mg/dL | 0.04 (-0.15, 0.23) | 0.03 (-0.16, 0.22) | -0.10 (-0.30, 0.09) | -0.12 (-0.30, 0.07) |
| HDL <40 mg/dL | 0.15 (-0.15, 0.45) | 0.11 (-0.20, 0.42) | 0.02 (-0.29, 0.33) | -0.04 (-0.34, 0.26) |
| Hypertension | 0.27 (0.03, 0.51)\* | 0.25 (0.00, 0.49) | 0.15 (-0.10, 0.40) | 0.10 (-0.15, 0.34) |
| Hyperglycemia | 0.38 (0.18, 0.58)\* | 0.32 (0.12, 0.52)\* | 0.24 (0.04, 0.44)\* | 0.19 (-0.01, 0.39) |
| **aBMD (g/cm2) FN:** MetS | 0.24 (0.04, 0.44)\* | 0.25 (0.06, 0.45)\* | - | -0.12 (-0.33, 0.09) |
| Waist >102 cm | 0.37 (0.18, 0.55)\* | 0.44 (0.25, 0.62)\* | 0.43 (0.23, 0.62)\* | -0.06 (-0.31, 0.19) |
| Triglycerides >150 mg/dL | -0.03 (-0.22, 0.16) | -0.10 (-0.29, 0.09) | -0.23 (-0.42, -0.04)\* | -0.26 (-0.44, -0.08)\* |
| HDL <40 mg/dL | 0.13 (-0.17, 0.42) | 0.10 (-0.20, 0.41) | 0.06 (-0.24, 0.37) | -0.06 (-0.34, 0.23) |
| Hypertension | -0.04 (-0.28, 0.20) | 0.10 (-0.15, 0.34) | -0.01 (-0.25, 0.23) | -0.07 (-0.31, 0.16) |
| Hyperglycemia | 0.26 (0.07, 0.46)\* | 0.33 (0.13, 0.52)\* | 0.28 (0.08, 0.48)\* | 0.18 (-0.01, 0.37) |
|  **aBMD (g/cm2) Total hip:** MetS | 0.31 (0.11, 0.51)\* | 0.34 (0.13, 0.54)\* | - | -0.09 (-0.30, 0.12) |
| Waist >102 cm | 0.49 (0.30, 0.68)\* | 0.55 (0.36, 0.74)\* | 0.54 (0.35, 0.74)\* | 0.02 (-0.22, 0.27) |
| Triglycerides >150 mg/dL | -0.01 (-0.20, 0.18) | -0.04 (-0.23, 0.15) | -0.19 (-0.38, 0.00) | -0.23 (-0.41, -0.05)\* |
| HDL <40 mg/dL | 0.12 (-0.18, 0.43) | 0.16 (-0.15, 0.47) | 0.08 (-0.23, 0.39) | -0.03 (-0.32, 0.26) |
| Hypertension | 0.04 (-0.20, 0.28) | 0.11 (-0.13, 0.36) | -0.01 (-0.25, 0.24) | -0.10 (-0.34, 0.13) |
| Hyperglycemia | 0.31 (0.11, 0.50)\* | 0.35 (0.15, 0.55)\* | 0.28 (0.08, 0.48)\* | 0.17 (-0.02, 0.36) |
| **pQCT: 50% radius** |  |  |  |  |
| **CSA**  |  |  |  |  |
| Waist >102 cm | 0.36 (0.18, 0.53)\* | 0.34 (0.16, 0.53)\* | 0.41 (0.22, 0.60)\* | 0.22 (-0.03, 0.47) |
| Triglycerides >150 mg/dL | -0.18 (-0.36, 0.00)\* | -0.18 (-0.37, 0.00) | -0.21 (-0.40, -0.02)\* | -0.26 (-0.44, -0.07)\* |
| HDL <40 mg/dL | -0.17 (-0.44, 0.10) | -0.18 (-0.46, 0.10) | -0.20 (-0.48, 0.08) | -0.23 (-0.51, 0.05) |
| Hypertension | -0.12 (-0.34, 0.11) | -0.16 (-0.40, 0.07) | -0.22 (-0.45, 0.01) | -0.28 (-0.52, -0.04)\* |
| Hyperglycemia | 0.12 (-0.07, 0.30) | 0.09 (-0.10, 0.28) | 0.07 (-0.13, 0.26) | 0.03 (-0.17, 0.23) |
| **Cortical thickness**  |  |  |  |  |
| Waist >102 cm | 0.21 (0.03, 0.38)\* | 0.28 (0.10, 0.47)\* | 0.27 (0.08, 0.46)\* | 0.13 (-0.12, 0.38) |
| Triglycerides >150 mg/dL | 0.06 (-0.12, 0.24) | 0.03 (-0.15, 0.21) | -0.02 (-0.22, 0.17) | -0.06 (-0.24, 0.13) |
| HDL <40 mg/dL | 0.08 (-0.21, 0.36) | 0.11 (-0.18, 0.39) | 0.06 (-0.24, 0.35) | 0.03 (-0.25, 0.32) |
| Hypertension | -0.04 (-0.27, 0.18) | 0.08 (-0.15, 0.31) | 0.03 (-0.21, 0.26) | -0.01 (-0.25, 0.22) |
| Hyperglycemia | -0.02 (-0.22, 0.17) | 0.04 (-0.15, 0.24) | 0.01 (-0.19, 0.20) | -0.04 (-0.23, 0.16) |
| **Cortical bone area**  |  |  |  |  |
| Waist >102 cm | 0.40 (0.23, 0.58)\* | 0.45 (0.27, 0.63)\* | 0.48 (0.29, 0.67)\* | 0.25 (0.00, 0.49) |
| Triglycerides >150 mg/dL | -0.08 (-0.26, 0.10) | -0.10 (-0.28, 0.08) | -0.17 (-0.36, 0.02) | -0.23 (-0.41, -0.05)\* |
| HDL <40 mg/dL | -0.03 (-0.31, 0.25) | -0.01 (-0.30, 0.28) | -0.05 (-0.34, 0.24) | -0.12 (-0.40, 0.17) |
| Hypertension | -0.06 (-0.28, 0.17) | 0.00 (-0.23, 0.23) | -0.08 (-0.31, 0.15) | -0.14 (-0.38, 0.09) |
| Hyperglycemia | 0.04 (-0.15, 0.23) | 0.07 (-0.13, 0.26) | 0.03 (-0.16, 0.22) | -0.04 (-0.24, 0.15) |
| **Stress strain index**  |  |  |  |  |
| Waist >102 cm | 0.40 (0.23, 0.58)\* | 0.42 (0.24, 0.60)\* | 0.48 (0.30, 0.67)\* | 0.30 (0.05, 0.55)\* |
| Triglycerides >150 mg/dL | -0.15 (-0.33, 0.03) | -0.15 (-0.34, 0.03) | -0.19 (-0.38, -0.01)\* | -0.26 (-0.44, -0.07)\* |
| HDL <40 mg/dL | -0.20 (-0.48, 0.07) | -0.20 (-0.49, 0.08) | -0.23 (-0.51, 0.06) | -0.29 (-0.58, -0.01)\* |
| Hypertension | -0.13 (-0.35, 0.10) | -0.11 (-0.34, 0.12) | -0.18 (-0.40, 0.05) | -0.23 (-0.47, 0.00) |
| Hyperglycemia | -0.01 (-0.20, 0.17) | 0.00 (-0.19, 0.19) | -0.02 (-0.21, 0.17) | -0.08 (-0.28, 0.11) |
| **Muscle area**  |  |  |  |  |
| Waist >102 cm | 0.56 (0.38, 0.73)\* | 0.68 (0.51, 0.84)\* | 0.61 (0.44, 0.79)\* | -0.23 (-0.44, -0.03)\* |
| Triglycerides >150 mg/dL | 0.17 (-0.01, 0.35) | 0.13 (-0.05, 0.30) | -0.06 (-0.23, 0.11) | -0.13 (-0.29, 0.02) |
| HDL <40 mg/dL | 0.30 (0.02, 0.59)\* | 0.32 (0.04, 0.59)\* | 0.20 (-0.07, 0.47) | 0.08 (-0.16, 0.32) |
| Hypertension | 0.07 (-0.15, 0.30) | 0.32 (0.11, 0.54)\* | 0.21 (-0.01, 0.42) | 0.00 (-0.19, 0.20) |
| Hyperglycemia | 0.07 (-0.12, 0.26) | 0.22 (0.04, 0.41)\* | 0.09 (-0.08, 0.27) | -0.05 (-0.21, 0.12) |

\**P*<0.05. Results are expressed as z-score β-coefficients (95% CI). † Model 1:Adjusted for age, centre, smoking, alcohol ‡ Model 2: Adjusted for age, centre, smoking, alcohol and other MetS components § Model 3: Adjusted for age, center, smoking, alcohol and BMI